DERMAX
ActiveSummary
DERMAX has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5.3m and a net result of €517,589. Equity is growing by about 25% per year across the filed financial years. Its solvency ranks better than 95% of 6,075 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Directors
Statutory auditor 1
Mandate history
- Statutory auditor
| Name | Functions and periods |
|---|---|
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES |
|
Owners and capital
Owners
1 ownerChain of control
- Hyloris Pharmaceuticals
- DERMAX
Highest known parent: Hyloris Pharmaceuticals. The sources do not say who stands above it.
Owners 1
-
100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.